LLY

1,011.28

-2.39%↓

JNJ

202.37

-1.51%↓

ABBV

228.23

-0.06%↓

UNH

334.44

-0.4%↓

AZN

90.21

-0.67%↓

LLY

1,011.28

-2.39%↓

JNJ

202.37

-1.51%↓

ABBV

228.23

-0.06%↓

UNH

334.44

-0.4%↓

AZN

90.21

-0.67%↓

LLY

1,011.28

-2.39%↓

JNJ

202.37

-1.51%↓

ABBV

228.23

-0.06%↓

UNH

334.44

-0.4%↓

AZN

90.21

-0.67%↓

LLY

1,011.28

-2.39%↓

JNJ

202.37

-1.51%↓

ABBV

228.23

-0.06%↓

UNH

334.44

-0.4%↓

AZN

90.21

-0.67%↓

LLY

1,011.28

-2.39%↓

JNJ

202.37

-1.51%↓

ABBV

228.23

-0.06%↓

UNH

334.44

-0.4%↓

AZN

90.21

-0.67%↓

Search

Simulations Plus Inc

Abrir

SetorSaúde

20.73 3.81

Visão Geral

Variação de preço das ações

24h

Atual

Mín

19.83

Máximo

20.74

Indicadores-chave

By Trading Economics

Rendimento

-70M

-67M

Vendas

-2.1M

20M

P/E

Médio do Setor

48.528

80.03

Rendimento de Dividendos

0.48

Margem de lucro

-330.585

Funcionários

243

EBITDA

327K

5.3M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+0.74% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

0.48%

2.29%

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-7M

344M

Abertura anterior

16.92

Fecho anterior

20.73

Sentimento de Notícias

By Acuity

56%

44%

310 / 374 Ranking em Healthcare

Simulations Plus Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

3 de dez. de 2025, 23:21 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

EQB to Buy Loblaw Unit PC Financial for About $573.5 Million -- Update

3 de dez. de 2025, 23:14 UTC

Aquisições, Fusões, Aquisições de Empresas

EQB to Buy PC Financial From Loblaw for About $573.5 Million

3 de dez. de 2025, 22:01 UTC

Grandes Movimentos do Mercado

Costco Wholesale Reports Higher Monthly Sales

3 de dez. de 2025, 21:38 UTC

Ganhos

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500 Million

3 de dez. de 2025, 23:59 UTC

Conversa de Mercado

Australian Coal Prices Seen Having Recovered Well -- Market Talk

3 de dez. de 2025, 23:49 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

3 de dez. de 2025, 23:49 UTC

Conversa de Mercado

HSBC Chair Appointment Unlikely to Have Material Operational Impact -- Market Talk

3 de dez. de 2025, 23:49 UTC

Conversa de Mercado

Nikkei May Decline Amid Caution Over U.S. Labor Market -- Market Talk

3 de dez. de 2025, 23:13 UTC

Conversa de Mercado

Australian Treasurer Says Economy Not On Drip of Govt Spending -- Market Talk

3 de dez. de 2025, 23:10 UTC

Ganhos

Salesforce Raises Forecast as Agentforce Sales Top $500M -- Update

3 de dez. de 2025, 23:08 UTC

Conversa de Mercado

Goodman's New Bull Sees Profit Upgrade on Cards -- Market Talk

3 de dez. de 2025, 23:06 UTC

Aquisições, Fusões, Aquisições de Empresas

EQB to Buy Loblaw Unit PC Financial for About $573.5M -- Update

3 de dez. de 2025, 22:59 UTC

Aquisições, Fusões, Aquisições de Empresas

EQB to Buy PC Financial From Loblaw for About $573.5M

3 de dez. de 2025, 22:45 UTC

Conversa de Mercado

WiseTech Investor Day Increases Bull's Confidence -- Market Talk

3 de dez. de 2025, 22:20 UTC

Ganhos

Salesforce CEO: 9,500 of 18,500 Total Closed Agentforce Deals Are Paid

3 de dez. de 2025, 22:19 UTC

Ganhos

Salesforce CEO: Six Out of 10 Biggest Deals in 3Q Came from Agentforce

3 de dez. de 2025, 22:17 UTC

Ganhos

Salesforce Working to Add Voice to Agentforce, CEO Says

3 de dez. de 2025, 22:16 UTC

Ganhos

Salesforce CEO: Williams-Sonoma's Agentforce Makes Up 60% of Customer Chats

3 de dez. de 2025, 22:15 UTC

Ganhos

Salesforce CEO: Agentforce ARR Was $540M in 3Q

3 de dez. de 2025, 22:10 UTC

Aquisições, Fusões, Aquisições de Empresas

EQB: Will Enter Into a Long-Term Strategic Relationship With Loblaw >EQB.T

3 de dez. de 2025, 22:09 UTC

Aquisições, Fusões, Aquisições de Empresas

EQB: Agreed to Acquire PC Fincl From Loblaw >EQB.T

3 de dez. de 2025, 21:50 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

3 de dez. de 2025, 21:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

3 de dez. de 2025, 21:49 UTC

Ganhos

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3 de dez. de 2025, 21:23 UTC

Ganhos

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500M

3 de dez. de 2025, 21:19 UTC

Ganhos

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3 de dez. de 2025, 21:06 UTC

Ganhos

Salesforce Reports Mixed Earnings. The Stock Is Rising. -- Barrons.com

3 de dez. de 2025, 21:04 UTC

Ganhos

Salesforce Sees Profitable Growth Framework Target of 50 by FY30 >CRM

3 de dez. de 2025, 21:04 UTC

Ganhos

Salesforce Targets $60 B Plus Organic Rev by FY30 >CRM

3 de dez. de 2025, 21:03 UTC

Ganhos

Salesforce Raises FY26 Oper Cash Flow Growth Guidance to 13% to 14% Y/Y >CRM

Comparação entre Pares

Variação de preço

Simulations Plus Inc Previsão

Preço-alvo

By TipRanks

0.74% parte superior

Previsão para 12 meses

Média 20.5 USD  0.74%

Máximo 25 USD

Mínimo 16 USD

Com base em 5 analistas de Wall Street que oferecem metas de preço de 12 meses para Simulations Plus Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

5 ratings

3

Comprar

2

Manter

0

Vender

Sentimento

By Acuity

310 / 374 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Baixa

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat